Immuneering Reports $24.2 Million Q3 Net Loss, Cash Runway Into Q4 2028
Immuneering reported a third-quarter 2026 net loss of $24.2 million, or $0.37 per share, versus a $15.0 million loss a year earlier. Cash, cash equivalents and marketable securities totaled $166.1 million at September 30.
Immuneering reported a third-quarter 2026 net loss of $24.2 million, or $0.37 per share, compared with a $15.0 million loss a year earlier. Cash, cash equivalents and marketable securities totaled $166.1 million at September 30, and the company expects its cash runway to extend into the fourth quar…